Author/Authors :
Hien, H Centre MURAZ - Unité de recherche Santé de la Reproduction VIH et Maladies Associées, Burkina Faso , Hien, H Institut de recherche en sciences de la santé, Burkina Faso , Meda, N Centre MURAZ - Unité de recherche Santé de la Reproduction VIH et Maladies Associées, Burkina Faso , Diagbouga, S Institut de recherche en sciences de la santé, Burkina Faso , Zoure, E CHU Souro Sanou - Département de pédiatrie, Burkina Faso , Yaméogo, S CHU Souro Sanou - Département de pédiatrie, Burkina Faso , Tamboura, H CHU Souro Sanou - Département de pédiatrie, Burkina Faso , Somé, J CHU Souro Sanou - Département de pédiatrie, Burkina Faso , Ouiminga, A Centre MURAZ - Unité de recherche Santé de la Reproduction VIH et Maladies Associées, Burkina Faso , Rouet, F Le Centre international de recherches médicales de Franceville (CIRMF), Gabon , Drabo, A Centre MURAZ - Unité de recherche Santé de la Reproduction VIH et Maladies Associées, Burkina Faso , Hien, A CHU Souro Sanou - Département de pédiatrie, Burkina Faso , Nicolas, J CHU - Département de Pédiatrie, France , Chappuy, H Université Paris Descartes, France , Van de Perre, P INSERM U - Infection by HIV and by agents with mucocutaneous tropism:from pathogenesis to prevention, France , Van de Perre, P Université Montpellier - CHU Montpellier - Département de bactériologievirologie, France , Msellati, P UMI 233, IRD/Université de Montpellier 1/Université Cheick Anta Diop Dakar/Université de Yaoundé, Cameroon , Nacro, B CHU Souro Sanou - Département de pédiatrie, Burkina Faso
Abstract :
Background: There is no data on long-term benefit of once-a-day antiretroviral therapy (ART) with combination of DDI, 3TC and EFV to allow its use in future therapeutic strategies. Objectives: To assess 24-month immuno-virological, adherence, tolerance, and effectiveness of a once-a-day ART with DDI, 3TC and EFV. Methods: A phase 2 open trial including 51 children aged from 30 months to 15 years, monitored a once-a-day regimen for 24 months from 2006 to 2008 in the Departement de Pediatrie du CHUSS, at Bobo-Dioulasso in Burkina Faso. We tested immunological and virological response, adherence, tolerance and resistance of the treatment. Results: Children with CD4 25% at 24 months were 67.4% (33/49) CI 95% [54%, 80%].The proportion of children with viral plasma RNA 300 cp / ml at 24 months of treatment was 81.6 % (40/49) CI [68.0% 91.2%]. Good adherence was obtained with more than 88% adherence 95% over the 24 months. Drugs were well tolerated. Conclusions: Given the limited number of antiretroviral drugs available in Africa and the inadequacy of laboratory monitoring in support program, once-a-day treatment and especially the DDI-based combination strategies could be an attractive operational option.
Keywords :
once , a , day therapy , Didanosine , Lamivudine , and Efavirenz , child.
